Search Results - "Ji, Niannian"

925 Chemokine malfunction: CCL2-nitration mediated dysfunction of T cells in bladder cancer by Mukherjee, Neelam, Ji, Niannian, Shu, Zhen-Ju, Hassouneh, Zaineb, Svatek, Robert S

“…BackgroundThe chemokine CCL2 (C-C motif ligand 2) is best known for its ability to induce the trafficking of immune cells by binding its primary receptor,…”
Get full text

Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial by Ji, Niannian, Mukherjee, Neelam, Morales, Edwin E., Tomasini, Maggie E., Hurez, Vincent, Curiel, Tyler J., Abate, Getahun, Hoft, Dan F., Zhao, Xiang-Ru, Gelfond, Jon, Maiti, Sourindra, Cooper, Laurence J.N., Svatek, Robert S.

“…Background: Intravesical bacillus Calmette-Guérin (BCG) is the gold standard immunologic agent for treating patients with high-grade non-muscle invasive…”
Get full text

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation by Reyes, Ryan M, Zhang, Chenghao, Deng, Yilun, Ji, Niannian, Mukherjee, Neelam, Padron, Alvaro S, Clark, Curtis A, Svatek, Robert S, Curiel, Tyler J

“…Bladder cancer (BC) and melanoma are amenable to immune checkpoint blockade (ICB) therapy, yet most patients with advanced/metastatic disease do not respond…”
Get full text

KLRF1, a novel marker of CD56bright NK cells, predicts improved survival for patients with locally advanced bladder cancer by Mukherjee, Neelam, Ji, Niannian, Tan, Xi, Chen, Chun‐Liang, Noel, Onika D. V., Rodriguez‐Padron, Maria, Lin, Chun‐Lin, Alonzo, David G., Huang, Tim H., Svatek, Robert S.

“…Background Bladder tumor‐infiltrating CD56bright NK cells are more tumor cytotoxic than their CD56dim counterparts. Identification of NK cell subsets is…”
Get full text

Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis by Ji, Niannian, Somanaboeina, Animesh, Dixit, Aakanksha, Kawamura, Kazuyuki, Hayward, Neil J, Self, Christopher, Olson, Gary L, Forsthuber, Thomas G

“…The strong association of HLA-DR2b (DRB1*1501) with multiple sclerosis (MS) suggests this molecule as prime target for specific immunotherapy. Inhibition of…”
Get full text

Bladder tumor ILC1s undergo Th17‐like differentiation in human bladder cancer by Mukherjee, Neelam, Ji, Niannian, Tan, Xi, Lin, Chun‐Lin, Rios, Emily, Chen, Chun‐Liang, Huang, Tim, Svatek, Robert S.

“…Purpose Human innate lymphoid cells (hILCs) are lineage‐negative immune cells that do not express rearranged adaptive antigen receptors. Natural killer (NK)…”
Get full text

CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation by Reyes, Ryan Michael, Deng, Yilun, Zhang, Deyi, Ji, Niannian, Mukherjee, Neelam, Wheeler, Karen, Gupta, Harshita B, Padron, Alvaro S, Kancharla, Aravind, Zhang, Chenghao, Garcia, Myrna, Kornepati, Anand V R, Boyman, Onur, Conejo-Garcia, Jose R, Svatek, Robert S, Curiel, Tyler J

“…BackgroundAnti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in <30% of patients. Interleukin…”
Get full text

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study by Ji, Niannian, Mukherjee, Neelam, Reyes, Ryan M, Gelfond, Jonathan, Javors, Martin, Meeks, Joshua J., McConkey, David J, Shu, Zhen-Ju, Ramamurthy, Chethan, Dennett, Ryan, Curiel, Tyler J, Svatek, Robert S

“…BackgroundAlthough intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory…”
Get full text

242 Pharmacologic tumor PD-L1 depletion with chlorambucil treats ovarian cancer and melanomas in a tumor PD-L1-dependent manner and renders αPD-L1-resistant tumors αPD-L1-sensitive by Bai, Haiyan, Padrón, Álvaro, Deng, Yilun, Kornepati, Anand, Polusani, Srikanth, Kari, Suresh, Murray, Clare, Garcia, Myrna, Reyes, Ryan, Ji, Niannian, Gupta, Harshita, Hart, Matthew, Curiel, Tyler

“…BackgroundProgrammed cell death ligand-1 (PD-L1) overexpression in tumor cells inhibits T cells activity and delivers pathologic intracellular signals that can…”
Get full text

719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer by Reyes, Ryan, Deng, Yilun, Zhang, Deyi, Ji, Niannian, Mukherjee, Neelam, Wheeler, Karen, Gupta, Harshita, Kancharla, Aravind, Garcia, Myrna, Kornepati, Anand, Svatek, Robert, Curiel, Tyler

“…BackgroundαPD-L1 bladder cancer (BC) immunotherapy is effective in <30% of cases.1 To address the large αPD-L1-unresponsive subset of patients, we tested…”
Get full text

Macrophage migration inhibitory factor promotes resistance to glucocorticoid treatment in EAE by Ji, Niannian, Kovalovsky, Andra, Fingerle-Rowson, Günter, Guentzel, M Neal, Forsthuber, Thomas G

“…OBJECTIVE:Glucocorticoids (GCs) are used as standard treatment for acute attacks of multiple sclerosis (MS). However, GCs eventually lose efficacy and do not…”
Get full text

Universal primer PCR with DGGE for rapid detection of bacterial pathogens by Ji, Niannian, Peng, Bo, Wang, Guizhong, Wang, Sanying, Peng, Xuanxian

“…A universal primer PCR (UPPCR) combined with denaturing gradient gel electrophoresis (DGGE) was evaluated as a method permitting the rapid detection of…”
Get full text

Nitration of CCL2 disrupts the tumor-protective function of CCL2 in bladder cancer by Mukherjee, Neelam, Ji, Niannian, Shu, Zhen-Ju, Curiel, Tyler J, Svatek, Robert S

“…Abstract The chemokine CCL2 (C-C motif ligand 2) is best known for its ability to induce trafficking of immune cells by binding its primary receptor, CCR2. The…”
Get full text

MP57-06 SURGICALLY-INDUCED STRESS ALTERS TUMOR SURVIVAL AND RESPONSE TO ADJUVANT IMMUNOTHERAPY IN BLADDER CANCER by Wheeler, Karen, Mukherjee, Neelam, Ji, Niannian, Svatek, Robert

Get full text

Aire is not essential for regulating autoimmune pathology in mice transgenic for human autoimmune-disease associated MHC class II genes HLA-DR2b and HLA-DR4 by Nalawade, Saisha A., Ji, Niannian, Kraig, Ellen, Forsthuber, Thomas

“…Abstract The human MHC class II molecules HLA-DR2b (DRB1*1501) and HLA-DR4 (DRB1*0401) are strongly linked to increased susceptibility to autoimmune diseases,…”
Get full text

CCL2/CCR2 signaling protects against bladder cancer growth in a T cell dependent manner by Mukherjee, Neelam, Ji, Niannian, Shu, Zhen-Ju, Curiel, Tyler J, Svatek, Robert S

“…Abstract The chemokine CCL2 (C-C motif ligand 2) is an important signaling axis underlying recruitment of pro-tumorigenic myeloid cells and is associated with…”
Get full text

ESTABLISHMENT OF A DOUBLE-HUMANIZED MOUSE MODEL USING PATIENT-DERIVED XENOGRAFT BLADDER CANCER TUMOR CELL LINE AND HUMAN γδ T-CELLS by Trecarten, Shaun, Svatek, Robert S., Ji, Niannian, Shu, Zhen-Ju, Curiel, Tyler J., Mukherjee, Neelam, Furman, Jamie

“…Despite recent breakthroughs of immune-checkpoint inhibitors in the management of bladder cancer (BC), only 20% of patients with non-muscle invasive BC (NMIBC)…”
Get full text

Development of autoreactive CD8+ T cells in Aire-deficient mice (101.38) by Ji, Niannian, Forsthuber, Thomas

“…Abstract Autoimmune regulator (Aire) regulates the transcription of a myriad of self antigens in the thymus, which is important for the process of central…”
Get full text

The kinetics of myelin antigen uptake by myeloid cells in the central nervous system during experimental autoimmune encephalomyelitis by Sosa, Rebecca A, Murphey, Cathi, Ji, Niannian, Cardona, Astrid E, Forsthuber, Thomas G

“…Induction of experimental autoimmune encephalomyelitis (EAE) in susceptible animals requires reactivation of encephalitogenic CD4(+) T cells by APCs in the…”
Get full text

Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer by Hassouneh, Zaineb, Noel, Onika D. V., Ji, Niannian, Kim, Michelle E., Svatek, Jordan, Svatek, Robert S., Risinger, April L., Mukherjee, Neelam

“…Despite its immunogenic nature, bladder cancer (BCa) responds sub-optimally to FDA-approved immunotherapy. Background/Objectives: We have previously shown that…”
Get full text